Introduction
While most colorectal cancers (CRCs) show chromosomal instability, approximately 15% of CRCs arise as a result of defective DNA mismatch repair (MMR).
1,2 These tumors show high-frequency microsatellite in stability (MSI-H) that occurs due to the inability of cells to repair single nucleotide DNA mismatches. MSI-H is a hallmark of Lynch syndrome (also referred to as hereditary nonpolyposis colorectal cancer [HNPCC] ) that results from germline mutation in MMR genes (MLH1, MSH2, MSH6, PMS2) 1 that are highly penetrant, yet account for less than 5% of all CRCs ( Figure 1 ). Amsterdam II criteria and the revised Bethesda guidelines were deve loped to identify individuals with Lynch syndrome and thus, likely to carry a germline mutation in one of the known MMR genes, most commonly MLH1 or MSH2. 3 The majority of MSI-H CRCs, however, are sporadic non Lynch syndrome cases that result from epigenetic inactivation of the MLH1 gene promoter by DNA hypermethylation ( Figure 1) . 2 These sporadic MSI-H CRCs often arise in the setting of a specific pathway of DNA hyper methylation, known as the CpG island methylator phenotype (CIMP) with CIMP-related silencing of MLH1. 4 Patients with MSI-H tumors have distinct clinical and pathological features, irrespective of their germline or sporadic origins, which include proximal colon predominance, frequent poor differentiation and mucinous histology, and increased numbers of tumorinfiltrating lymphocytes. 5, 6 In addition to being molecularly distinct from Lynch syndrome cases, patients with sporadic MSI-H cancers have associated epide miological features, including older age at diagnosis, female gender and cigarette smoking. 2 MSI testing can be performed on paraffinembedded tumor tissue using a PCRbased assay for detection of instability at selected microsatellite loci. 5, 7 A panel of five microsatellites have been validated and recommended as a reference panel. 8 CRCs can be characterized on the basis of: MSI-H, if two or more of the five microsatellite markers show instability (that is, have insertion/deletion mutations), lowfrequency MSI (MSI-L) if only one of the five markers shows instability, and microsatellite stable (MSS) if none of the markers show instability. 8 
Impact of MMR deficiency
When MSI was first identified in CRCs, it was noted that patients with MSI-H tumors had better survival rates compared with those who had MSS or MSI-L tumors. 5 Moreover, patients with MSI-H tumors were found to have lower tumor stage at diagnosis and rarely had metastatic disease. Since the initial discovery of MSI in CRC, substantial data have accumulated that demonstrate the better outcome of patients with MMRdeficient CRC compared with patients who have MMR-proficient tumors. These data are largely from retrospective studies, [10] [11] [12] [13] but also include a population-based study 14 and a meta-analysis 15 where patients with MMR-deficient CRCs had a more favorable stage-adjusted survival compared with patients who had MMR-proficient tumors. The meta-analysis included 32 studies of 1,277 patients with MMR-deficient CRCs; a 35% reduction in the risk of death for patients with MMR-deficient tumors versus those with MMR-proficient tumors was demonstrated. 15 This analysis included untreated patients as well as patients treated with 5-fluorouracil (5-FU)-based adjuvant therapy in phase III randomized trials. More recently, 1,436 patients with stage II CRCs were treated in the QUASAR adjuvant therapy trial; the tumors of these patients were analyzed for MMR status and used as a validation cohort. 12 Multivariate analysis revealed that MMR deficiency was an indepen dent prognostic variable for 
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The author declares no competing interests. 16 Despite these findings, some studies, 17, 18 have not found an association of MMR deficiency with a favorable outcome, including a cooperative group trial 18 whereby no survival diffe rences were found for patients with MMR-deficient colon cancers compared with those who had MMR-proficient tumors. Factors that may account for these discrepant data include an insufficient sample size because patients with MMR-deficient tumors represent a rela tively small subset of cases, and the modest magnitude of the MMR prognostic effect. Furthermore, a selection bias can be introduced into adjuvant clinical trials because tissue samples are only available for a subset of patients. In addition, the MSI markers that are used to detect MSI-H cases have been variable and their sensitivity and specificity to detect MSI differ. 8 It is possible, therefore, that false-positive MSI results may dilute an already modest prognostic impact.
Predictive role of 5-FU therapy
Results from randomized phase III clinical trials and a prospective study have shown that MMR status is predictive of response to adjuvant 5-FU-based chemotherapy in patients with CRC. [19] [20] [21] Patients with MMRdeficient tumors did not derive benefit from adjuvant 5-FU-based chemo therapy, whereas those with MMR-proficient tumors had a significant survival benefit with this treatment. [19] [20] [21] Similarly, a meta-analysis that included patients with stage II and III CRCs who participated in randomized phase III clinical trials also demon strated that patients with MSI-H tumors did not derive benefit from adjuvant 5-FU therapy compared with non-MSI-H cases. 15 These data are consistent with preclinical studies, which have demonstrated that human CRC cell lines with MSI-H display resistance to compounds that induce DNA damage, such as 5-FU. 22 Resistance to 5-FU has been shown to be overcome by the restoration of normal DNA MMR function in CRC cells. 23 The predictive utility of MSI, however, has generated controversy given that some retro spective studies have failed to demon strate a predictive impact of MSI, 17, 18 and some reports 24, 25 have suggested that patients with MMR-deficient CRCs may have a greater benefit from adjuvant 5-FU-based treatment compared with those who have MMR-proficient tumors. In addition to a potential selection bias in these studies, it is important to recognize that the favorable prog nosis of patients with MMRdeficient tumors may result in an equivalent outcome as observed for patients with MMR-proficient tumors, given the lack of benefit from 5-FU in MMR-deficient cases. In a recent study, aimed at valida ting the prognostic and predictive impact of MMR status, tumors from a large series of patients with stage II and III colon cancers from North American and european adjuvant therapy trials were analyzed for MMR status. 26 Study data were pooled and among patients who received surgery alone (n = 515), those with MMR-deficient tumors had a 49% improvement in disease-free survival (DFS) and better overall survival compared to those with MMR proficient tumors. 26 Furthermore, this study confirmed that patients with MMRdeficient tumors do not benefit from 5-FU therapy compared to patients with MMRdeficient tumors who were rando mized to untreated control arms. 26 In an adjuvant chemotherapy trial (CALGB 89803), 27 the impact of MSI status upon clinical outcome was studied in patients with stage III colon cancer treated with irinotecan, 5-FU, and leucovorin (Lv), known as IFL, versus 5-FU/Lv. Patients with MMR-deficient tumors who were treated with IFL had a significantly improved 5-year DFS compared with those who had MMR-proficient tumors who were treated with IFL. However, a similar relationship was not observed for patients treated with 5-FU/Lv. In patients with MMR-deficient tumors, a trend toward longer DFS was seen with IFL versus 5-FU/Lv; median DFS or overall survival, however, has not yet been reached in this trial. These data suggest that the addition of irinotecan may improve the clinical outcome of patients with MMRdeficient colon cancers. However, data from the Pan european Trial Adjuvant Colon Cancer (PeTACC-3), which was designed to determine whether the addition of irinotecan to 5-FU/Lv could improve DFS, failed to show a benefit with irinotecan in patients with MSI-H colon cancers. 28 The results from this study contrast with the findings reported in the CALGB 89803 trial. Since all patients received 5-FU in the PeTACC-3 study, the benefit, or lack thereof, of 5-FU therapy alone in patients with MSI-H tumors cannot be addressed, except to indicate that MSI-H remained prog nostic despite treatment in this study. 28 It is important to note that neither study found an overall survival benefit with the addition of irinotecan to 5-FU/Lv. The addition of irinotecan in the CALGB 89803 trial was associated with increased lethal and nonlethal toxic effects, with deaths that were primarily attributed to neutropenic sepsis or vascular thromboembolic events. 29 Thus, irinotecan cannot be recommended as an adjuvant therapy regimen for patients with CRC, although it is an effective treatment for patients with metastatic CRC.
Therapy and patient selection
The use of adjuvant chemotherapy in patients with curatively resected stage II (lymph-node negative) colon cancer remains controversial, and represents a dilemma for medical oncologists with regard to the potential benefits versus risks of treatment. It is estimated that one-third 30 At present, available data do not justify the exclusion of patients with stage III MMR-deficient CRC from receiving adjuvant FOLFOX chemotherapy since the responsiveness of these tumors to oxaliplatin or FOLFOX is unknown and remains an important research question. A phase III clinical trial assessing the FOLFOX regimen in patients with stage II colon cancers (eCOG 5202) is ongoing; patients are categorized into low-risk (MSI-H or chromosome 18q intact) or high-risk (MSS, MSI-L or 18q allelic imbalance) groups. Low-risk patients receive observation, whereas highrisk patients are treated with FOLFOX with or without the anti-veGF antibody, bevaci zumab. Bevacizumab has been shown to enhance the efficacy of 5-FU-based therapy in patients with metastatic CRC. 31 Regrettably, this trial will not provide data on the responsiveness of MSI-H tumors to FOLFOX therapy, since patients with MSI-H tumors are not being treated.
CRCs with deficient DNA MMR
Our group developed a model to predict MMR deficiency using clinical and pathological data available in routine clinical practice in order to identify patients with sporadic MMR-deficient CRC and to utilize such information for clinical decisionmaking. Data from 982 patients with stage II and III colon cancer who participated in six adjuvant 5-FU-based therapy trials was analyzed; MMR deficiency was detected in 4% of patients with distal tumors, as defined relative to splenic flexure. 32 Therefore, the author recommends that testing for MMR status by MSI analysis or IHC be performed on all resected, stage II cancers of the proximal colon in patients where adjuvant therapy is a consideration. It could be argued that the cost of MMR testing may be offset by more-efficient use of adjuvant chemotherapy. 33 MMR status in patients with stage III disease is of research interest, but should not be used to inform adjuvant treatment decisions at the present time. Since loss of hMLH1 protein expression can be due to promoter hypermethylation or a germline mutation, MMR testing should also include hMLH1 promoter methylation analysis, which is a sensitive test. 2 Somatic BRAF (v600e) mutation analysis should also be performed since activation of the BRAF oncogene, a member of the RAS/RAF family of kinases, by the v600e mutation is characteristic of sporadic colon cancers with MSI, and has been shown to associate with the silencing of the MLH1 gene by hypermethylation. 34 By contrast, activating mutations in BRAF are not found in Lynch syndrome tumors and therefore, these analyses can be used to distinguish Lynch syndrome from sporadic CRC cases. 35 It is important to emphasize that loss of MMR proteins other than MLH1, as detected by IHC, suggests Lynch syndrome. Specifically, only the MLH1 MMR gene has been shown to be methylated in sporadic CRCs with MMR deficiency and loss of MSH2, MSH6 or PMS2 proteins suggests a germline mutation in the genes encoding these proteins and Lynch syndrome. 9 Patients with suspected hereditary CRC should be referred for genetic counseling, where the identifi cation of germline mutations and evalu ation/screening of family members can be appropriately addressed.
Conclusions
The determination of MMR status in patients with CRC can provide valuable prognostic and predictive information, and can help in clinical decision-making. Specifically, the favorable prognosis of patients with stage II MMR-deficient CRCs and the lack of benefit from adjuvant 5-FU-based therapy, indicate that these patients should not receive adjuvant chemo therapy. While data for patients with stage III MMR-deficient CRCs suggest a lack of benefit from 5-FU alone, the benefit of the current standard FOLFOX regimen in this patient subgroup awaits further investigation. Use of MMR status to guide patient management represents a further step toward personalized cancer care. 
